My ageing mind might be playing tricks, but I seem to recall that JP was asked about why Acadia hadn't pursued Fragile X with trofinetide and the response was that the phase 2 trial didn't provide robust enough results.
Was that at the AGM or in a webinar or a figment of my imagination?
My ageing mind might be playing tricks, but I seem to recall...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.39 |
Change
-0.470(2.37%) |
Mkt cap ! $2.478B | |||
| Open | High | Low | Value | Volume |
| $19.70 | $19.77 | $19.28 | $10.38M | 534.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 2680 | $19.35 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.41 | 362 | 1 |
View Market Depth
| Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |